Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
BACKGROUND
Vascular endothelial growth factor (VEGF) is an important stimulator of choroidal neovascularization (CNV). Bevacizumab (Avastin), ranibizumab (Lucentis) and pegaptanib sodium (Macugen) are anti-VEGF medications that have been used in the treatment of CNV. The purpose of our study is to evaluate the efficacy and safety of intravitreal injections of bevacizumab, ranibizumab and pegaptanib sodium in the treatment of CNV in a rat model.


METHODS
Multiple CNV lesions were induced by laser photocoagulation of the retina in Brown-Norway rats. After 3 weeks, 17 rats were divided into three groups and received intravitreal injections of bevacizumab, ranibizumab or pegaptanib sodium in different dosages. The lesions were evaluated by fluorescein angiography 1, 7, 14, and 28 days later to assess the efficacy of these medications.


RESULTS
Different doses of bevacizumab did not show any effect on stopping the leakage on fluorescein angiography on days 1, 7, 14, and 28. Ranibizumab and pegaptanib sodium did not stop the leakage of CNV either. No angiographic or histopathologic toxicity was observed.


CONCLUSIONS
These three anti-VEGF agents did not show any therapeutic effect on stopping CNV leakage in rats. Previous experiments with ranibizumab in monkeys resulted in a significant decrease in leakage of CNV. The difference may be due to the fact that both ranibizumab and bevacizumab are humanized and species-specific. There are several studies evaluating the effect of bevacizumab in non-primates. Since bevacizumab is humanized, the results of studies on non-primates may not be similar to humans and non-human primates.
Lu
Fang
F
Department of Ophthalmology and Visual Science, Yale University, School of Medicine, 40 Temple Street, Suite 3D, New Haven, CT 06510, USA.
Adelman
Ron A
RA
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000494:pharmacology; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005451:Fluorescein Angiography; D007267:Injections; D008028:Light Coagulation; D008268:Macular Degeneration / Q000188:drug therapy / Q000473:pathology; D000069579:Ranibizumab; D051381:Rats; D011914:Rats, Inbred BN; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab
Arch Ophthalmol. 2002 Mar;120(3):338-46
11879138
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):522-7
18234994
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2545-52
17525183
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2814-23
17525217
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3158-64
10967078
J Biol Chem. 1990 Dec 25;265(36):22071-4
2266109
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5708-15
18055823
Br J Ophthalmol. 1997 Feb;81(2):154-62
9059252
J Biol Chem. 2006 Mar 10;281(10):6625-31
16373345
Br J Ophthalmol. 2007 Jun;91(6):804-7
17179168
An Acad Bras Cienc. 2007 Sep;79(3):389-94
17768531
Ophthalmology. 1997 Jan;104(1):7-21
9022098
Vision Res. 1979;19(5):569-88
483586
Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2384-91
12091441
Invest Ophthalmol Vis Sci. 2006 Feb;47(2):462-74
16431938
Invest Ophthalmol Vis Sci. 1999 Feb;40(2):459-66
9950606
Invest Ophthalmol Vis Sci. 1998 Feb;39(2):391-6
9477999
J Biol Chem. 1990 Nov 15;265(32):19461-6
2246236
Arch Ophthalmol. 2001 Mar;119(3):399-404
11231773
Growth Factors. 1992;7(1):53-64
1380254
Am J Ophthalmol. 2008 Feb;145(2):249-256
18067876
J Cell Physiol. 1991 Oct;149(1):50-9
1719003